Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2025-09-05 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于恩那罗（恩那度司他片）新增适应症获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a new drug indication by the National Medical Products Administration (NMPA) in China. It details the drug's new approved use, regulatory approval, and potential impact on the company. The document is short (1226 characters) and serves as a formal announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor presentation content. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and company disclosure obligations.
2025-09-05 Chinese
关于SAL0140药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1150 characters) from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a drug (SAL0140) by the National Medical Products Administration. It contains no financial data, no detailed financial statements, or management discussion. It is an official regulatory announcement about a clinical trial application acceptance, not a financial report or earnings release. The document is an announcement of a regulatory event related to drug development, fitting best under Regulatory Filings (RNS) as it does not fit other categories like Annual Report, Earnings Release, or Capital Update. The document is not a report publication announcement since it is the announcement itself, but it is not a financial report. Therefore, the best classification is Regulatory Filings (RNS).
2025-08-28 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and references the full half-year report for comprehensive details. The length is 2695 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and includes actual financial statements and analysis. It is not merely an announcement or a certification, so it is not RPA or RNS. Hence, the correct classification is IR with high confidence. H1 2025
2025-08-19 Chinese
关于参与认购股权投资基金份额的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. about its participation in subscribing to shares of a private equity investment fund. It includes extensive information about the investment fund, the involved parties, the investment amount, the board resolution approving the investment, the investment purpose, risks, and other related details. The document is an announcement of a capital investment transaction by the company, describing the company's acquisition of a limited partnership interest in a private equity fund. It is not a financial report, earnings release, or management discussion. It is not a regulatory filing about governance or board changes, nor is it a voting result or proxy statement. The document is a capital/financing update about the company's investment activities and capital allocation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 13,000 characters and contains substantive content about the financing transaction, not just a brief notice or report publication announcement.
2025-08-19 Chinese
第六届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of the company's 2025 semi-annual report and a special report on the use of raised funds. It states that the Supervisory Board has reviewed and approved the 2025 semi-annual report and related financial and fundraising reports. The document is relatively short (1206 characters) and mainly announces the approval and availability of these reports on external media and websites. It does not contain the actual financial statements or detailed financial data itself, but rather certifies and announces the approval of these reports. According to the 'Menu vs Meal' rule, this is an announcement of the report rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a formal regulatory announcement about the approval and disclosure of the semi-annual report and fundraising report, not the full interim report itself.
2025-08-19 Chinese
第六届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 13th meeting of the 6th Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes approval of the 2025 semi-annual report and related financial reports, as well as decisions on investment participation. The document is relatively short (1372 characters) and primarily serves as a notice of board meeting decisions rather than the full semi-annual report itself. It references where the full reports can be found (e.g., on www.cninfo.com.cn) but does not contain the actual financial statements or detailed analysis. Therefore, this document is best classified as a Board/Management Information announcement (MANG) because it reports on board meeting resolutions and decisions, including approval of reports, rather than the reports themselves.
2025-08-19 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.